Meredith S. Manning's most recent trade in Soleno Therapeutics Inc was a trade of 1,922 Common Stock done at an average price of $50.0 . Disclosure was reported to the exchange on Dec. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.95 per share. | 15 Dec 2025 | 1,922 | 43,429 (0%) | 0% | 50.0 | 96,004 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.31 per share. | 27 Mar 2025 | 37,000 | 82,351 (0%) | 0% | 46.3 | 1,713,470 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 67.04 per share. | 27 Mar 2025 | 37,000 | 45,351 (0%) | 0% | 67.0 | 2,480,436 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 37,000 | 91,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 68.79 per share. | 27 Mar 2025 | 2,599 | 47,270 (0%) | 0% | 68.8 | 178,780 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 67.70 per share. | 27 Mar 2025 | 1,976 | 49,869 (0%) | 0% | 67.7 | 133,777 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 69.84 per share. | 27 Mar 2025 | 1,505 | 45,765 (0%) | 0% | 69.8 | 105,105 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 66.79 per share. | 27 Mar 2025 | 1,087 | 51,845 (0%) | 0% | 66.8 | 72,602 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 65.97 per share. | 27 Mar 2025 | 668 | 52,932 (0%) | 0% | 66.0 | 44,067 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 71.74 per share. | 27 Mar 2025 | 225 | 45,385 (0%) | 0% | 71.7 | 16,142 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 70.74 per share. | 27 Mar 2025 | 155 | 45,610 (0%) | 0% | 70.7 | 10,964 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 72.65 per share. | 27 Mar 2025 | 34 | 45,351 (0%) | 0% | 72.6 | 2,470 | Common Stock |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 29,200 | 29,200 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 13,600 | 53,600 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | Meredith S. Manning | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 40,000 | 40,000 (0%) | 0% | 0 | Common Stock |